South Korea’s beauty and healthcare product maker Huons Global said on Wednesday its independently developed botulinum toxin (BTX) has been launched in Korea under the marketing name of Liztox. The product is the fourth home-grown BTX approved in Korea.

The company said the BTX product demonstrated efficacy and safety in all required clinical trials in Korean subjects, demonstrating its clinical usefulness in the improvement of moderate to severe glabellar wrinkles. The product was approved by the Ministry of Food and Drug Safety for domestic sale in April. It is already exported to Southeast Asia, the Middle East and Latin America under the brand name of Hutox, the company said. Additional export contracts were signed with partners in Europe and China last year.

Huons Global said Liztox will be co-marketed by its subsidiary Huons and aesthetic company Humedix in Korea where competition is fierce among BTX manufacturers.

Huons Global also aims to further increase penetration into the domestic beauty and cosmetics market in addition to its leadership driven by hyaluronic acid filler injection and medical equipment sales.

Huons Global said it is conducting a phase 3 study of the product for an additional indication to improve eye wrinkles in Korea, and is expected to receive regulatory approval in 2020.

By Kim Byung-ho and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]